NASDAQ:FHTX Foghorn Therapeutics Q3 2026 Earnings Report $1.99 -0.10 (-4.78%) Closing price 04:00 PM EasternExtended Trading$1.96 -0.03 (-1.51%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Foghorn Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.23Beat/MissN/AOne Year Ago EPSN/AFoghorn Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$6.39 millionBeat/MissN/AYoY Revenue GrowthN/AFoghorn Therapeutics Announcement DetailsQuarterQ3 2026Date11/4/2026TimeBefore Market OpensConference Call DateMonday, November 2, 2026Conference Call Time9:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Foghorn Therapeutics Earnings HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXOctober 8 at 10:00 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXOctober 6 at 5:20 PM | globenewswire.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.October 8 at 1:00 AM | Profits Run (Ad)What is HC Wainwright's Forecast for FHTX FY2027 Earnings?October 6 at 6:29 AM | americanbankingnews.comFoghorn Drops FHD-909 Development After Phase 1, Shifts Focus To Proprietary PipelineOctober 5 at 7:23 AM | rttnews.comHC Wainwright Has Lowered Expectations for Foghorn Therapeutics (NASDAQ:FHTX) Stock PriceOctober 4, 2026 | americanbankingnews.comSee More Foghorn Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Foghorn Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Foghorn Therapeutics and other key companies, straight to your email. Email Address About Foghorn TherapeuticsFoghorn Therapeutics (NASDAQ:FHTX) is a clinical-stage biotechnology company focused on developing medicines that target the chromatin regulatory system, which helps control how genes are expressed. The company’s research is aimed primarily at cancer and other diseases in which abnormalities in gene regulation contribute to disease progression. Foghorn uses its proprietary Gene Traffic Control platform to study interactions among chromatin-regulating proteins and identify potential drug targets. Its product candidates have included therapies designed to inhibit or degrade components of the chromatin remodeling machinery, including programs directed at BRD9 and LSD1. These investigational medicines have been evaluated in clinical studies for selected cancers, although the company’s development priorities and pipeline may change as research progresses. Founded in 2015 and headquartered in Cambridge, Massachusetts, Foghorn was established by researchers including Cigall Kadoch and Gerald Crabtree, whose work helped advance understanding of chromatin biology. The company conducts biotechnology research and clinical development intended for use in global healthcare markets. Adrian Gottschalk has served as the company’s president and chief executive officer.View Foghorn Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
